RS-1 stimulates the binding of hRAD51 to ssDNA. Low-micromolar concentrations of this small molecule enhance DNA binding and result in longer protein–DNA complex lengths. In addition, RS-1 stabilizes the active form of hRAD51 filaments and this is reflected in an enhanced strand assimilation activity.
|Cell lines||PC3 cells|
|Preparation method||PC3 cells were treated with 60 μM RS-1 for the indicated times. Cells were collected and fixed in ice cold 70% ethanol for at least 4 hours. Cells were rinsed and stained with 50 μg/ml PI, 50 μg/ml RNAse A in PBS for 20 minutes. Cell cycle distributions were analyzed by flow cytometry using a LSR-II (BD biosciences) cytometer. The percentage of cells in G1, S, and G2/M phases of the cell cycle was determined using FlowJo software.|
|Incubation time||24 h|
|Animal models||Athymic nude mice|
|Formulation||30% DMSO, 35% PEG-400, 35% PBS|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||100 mg/mL in DMSO|
RS-1 enhances CRISPR/Cas9- and TALEN-mediated knock-in efficiency.
Song J, et al. Nat Commun. 2016 Jan 28;7:10548. PMID: 26817820.
The RAD51-stimulatory compound RS-1 can exploit the RAD51 overexpression that exists in cancer cells and tumors.
Mason JM, et al. Cancer Res. 2014 Jul 1;74(13):3546-55. PMID: 24753542.
AM-0902 is a potent, selective antagonist of TRPA1 with IC50s of 71 and 131 nM for rTRPA1 and hTRPA1, respectively.
BMS-813160 is the first dual CCR2/CCR5 antagonist to enter clinical development for cardiovascular.
BMS-986205 is a selective indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor.
VU6005649 is a CNS penetrant mGlu7/8 receptor agonist with EC50s of 0.65 μM and 2.6 μM for mGlu7 receptor and mGlu8 receptor, respectively.
TLR7-agonist-1 is a potent and selective Toll-like Receptor 7 (TLR7) agonist with a LEC of 0.4 μM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.